Hypertension affects over one billion adults across the world with a majority in economically developing countries. Over the past four decades the development of orally active renin inhibitors for the treatment of hypertension has been a tremendous challenge for the pharmaceutical industry. In this time frame only aliskiren, in 2007, was approved by the FDA.  Our studies into the optimization of iminotetrahydropyrimidinones as orally active renin inhibitors by their elaboration into the S3sp of renin will be detailed.

Iminotetrahydropyrimidinones as renin inhibitors: A foray into the S3sp of renin

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.